TY - JOUR
T1 - Management of Obesity and Nonalcoholic Fatty Liver Disease
T2 - A Literature Review
AU - Hashem, Anas
AU - Khalouf, Amani
AU - Acosta, Andres
N1 - Funding Information:
A.A. is supported by NIH (NIH K23-DK114460, C-Sig P30DK84567), ANMS Career Development Award, Mayo Clinic Center for Individualized Medicine—Gerstner Career Development Award and Magnus Trust.
Publisher Copyright:
© 2021 Thieme Medical Publishers, Inc.. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - With the recent urbanization and globalization, the adult obesity rate has been increasing, which was paralleled with a dramatic surge in the incidence and prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD poses a growing threat to human health as it represents the most common cause of chronic liver disease in developed countries. It encompasses a wide spectrum of conditions starting from a build-up of fat in hepatocytes (steatosis), to developing inflammation (steatohepatitis), and reaching up to cirrhosis. It is also associated with higher rates of cardiovascular mortalities. Therefore, proper timely treatment is essential and weight loss remains the cornerstone in the treatment of obesity-related liver diseases. When diet, exercise, and lifestyle changes are not successful, the current recommendation for weight loss includes antiobesity medications and bariatric endoscopic and surgical interventions. These interventions have shown to result in significant weight loss and improve liver steatosis and fibrosis. In the current literature review, we highlight the expected outcomes and side effects of the currently existing options to have a weight-centric NAFLD approach.
AB - With the recent urbanization and globalization, the adult obesity rate has been increasing, which was paralleled with a dramatic surge in the incidence and prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD poses a growing threat to human health as it represents the most common cause of chronic liver disease in developed countries. It encompasses a wide spectrum of conditions starting from a build-up of fat in hepatocytes (steatosis), to developing inflammation (steatohepatitis), and reaching up to cirrhosis. It is also associated with higher rates of cardiovascular mortalities. Therefore, proper timely treatment is essential and weight loss remains the cornerstone in the treatment of obesity-related liver diseases. When diet, exercise, and lifestyle changes are not successful, the current recommendation for weight loss includes antiobesity medications and bariatric endoscopic and surgical interventions. These interventions have shown to result in significant weight loss and improve liver steatosis and fibrosis. In the current literature review, we highlight the expected outcomes and side effects of the currently existing options to have a weight-centric NAFLD approach.
KW - bariatric surgery
KW - nonalcoholic fatty liver disease
KW - nonalcoholic steatohepatitis
KW - obesity
KW - weight loss
UR - http://www.scopus.com/inward/record.url?scp=85110491787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110491787&partnerID=8YFLogxK
U2 - 10.1055/s-0041-1731704
DO - 10.1055/s-0041-1731704
M3 - Review article
C2 - 34243193
AN - SCOPUS:85110491787
SN - 0272-8087
VL - 41
SP - 435
EP - 447
JO - Seminars in liver disease
JF - Seminars in liver disease
IS - 4
ER -